OmniAb, Inc. (OABI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

OmniAb, Inc. (OABI) Healthcare & Pipeline Overview

OmniAb, Inc. specializes in therapeutic antibody discovery through its innovative OmniAb platform, utilizing genetically modified transgenic animals to produce human-sequence antibodies, positioning itself as a key player in the biotechnology sector for next-generation therapeutics.

What Is the Investment Thesis for OABI?

OmniAb, Inc. presents a unique investment thesis driven by its proprietary antibody discovery platform, which leverages transgenic animals to produce human-sequence antibodies. The company’s market capitalization stands at $573M, with a gross margin of 35.5%, indicating a solid foundation for future growth. Key growth catalysts include the increasing demand for bispecific antibodies and the expansion of its product offerings, particularly in complex therapeutic areas. As the biotechnology market continues to grow, projected to reach $2.4 trillion by 2028, OmniAb's innovative solutions position it well to capture a significant share of this expanding market. However, investors should remain aware of the high operational costs reflected in its profit margin of -187.7%, which may impact short-term profitability. Overall, OmniAb's unique technology and strategic partnerships are poised to drive long-term value creation.

Based on FMP financials and quantitative analysis

OABI Key Highlights

Market Cap of $573M, indicating a solid foundation for growth in the biotechnology sector.

• Gross margin of 35.5%, showcasing the company's ability to maintain profitability despite operational challenges.
• Employee count of 114, reflecting a lean operational structure focused on innovation.
• No dividend yield, indicating a reinvestment strategy to fuel growth and development.
• Beta of 0.87, suggesting lower volatility compared to the broader market.

Who Are OABI's Competitors?

OABI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are OABI's Key Strengths?

Innovative proprietary technology for antibody discovery.

• Strong focus on R&D and product development.
• Established partnerships with leading pharmaceutical companies.

What Are OABI's Weaknesses?

High operational costs impacting profitability.

• Limited market presence compared to larger competitors.
• Dependence on partnerships for revenue generation.

What Could Drive OABI Stock Higher?

OABI catalyst: Expansion of the OmniAb platform to include additional transgenic animal models for enhanced therapeutic applications.

• Strategic partnerships with pharmaceutical companies to co-develop novel therapeutics.
• Research and development initiatives aimed at expanding the product pipeline.

What Are the Key Risks for OABI?

Negative return on equity (-16.6%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 4 of the last 8 reported quarters.
• High operational costs may impact short-term profitability and cash flow.
• Intense competition in the biotechnology sector could affect market share.
• Regulatory hurdles in the approval process for new therapeutics could delay product launches.

What Are the Growth Opportunities for OABI?

• Growth opportunity 1: The global bispecific antibodies market is projected to reach $10.7 billion by 2026, driven by increasing applications in oncology and autoimmune diseases. OmniAb's OmniFlic and OmniClic platforms uniquely address this demand through their innovative common light chain approach, positioning the company to capture significant market share as the industry expands.
• Growth opportunity 2: The rising prevalence of chronic diseases is expected to boost the demand for innovative therapeutic solutions, with the global antibody therapeutics market anticipated to grow from $150 billion in 2023 to over $300 billion by 2030. OmniAb's focus on developing human-sequence antibodies aligns with this trend, providing a robust pipeline for future growth.
• Growth opportunity 3: Strategic partnerships with pharmaceutical companies can enhance OmniAb's market presence and accelerate product development timelines. Collaborations aimed at leveraging its proprietary transgenic technology can lead to co-developed therapies, expanding its product offerings and market reach.
• This influx of capital can facilitate the development of next-generation therapeutics and strengthen its competitive position.
• Growth opportunity 5: Expansion into international markets, particularly in Europe and Asia, can provide OmniAb with new revenue streams. As global healthcare systems increasingly adopt innovative therapies, OmniAb's unique antibody discovery platform can meet the growing demand for effective treatments in these regions.

What Threats Does OABI Face?

• Intense competition from established biotechnology firms.
• Rapid technological advancements may outpace current capabilities.
• Regulatory challenges in the biotechnology sector.

What Are OABI's Competitive Advantages?

• Proprietary transgenic animal technology differentiates its offerings.
• Strong focus on innovation and R&D enhances competitive positioning.
• Established partnerships with industry leaders bolster credibility and market reach.

What Does OABI Do?

Founded in 2012, OmniAb, Inc. is a biotechnology firm headquartered in Emeryville, California, dedicated to advancing therapeutic antibody discovery technologies. The company has developed an innovative platform known as OmniAb, which harnesses the biological intelligence of proprietary transgenic animals, including the OmniRat, OmniChicken, and OmniMouse. These genetically modified organisms are designed to generate antibodies with human sequences, a critical requirement for the development of human therapeutic candidates. The OmniAb platform not only provides access to diverse antibody repertoires but also incorporates advanced screening technologies that facilitate the discovery of next-generation therapeutics. Notably, OmniAb's OmniFlic and OmniClic products cater to the industry's growing demand for bispecific antibody applications through a common light chain approach, while the OmniTaur features unique structural attributes of cow antibodies, making it suitable for addressing complex targets. With a workforce of 114 employees, OmniAb is strategically positioned to collaborate with industry partners, enhancing its role in the biotechnology landscape. The company's commitment to innovation and its focus on addressing unmet medical needs underscore its potential for growth in the competitive biotechnology sector.

What Products and Services Does OABI Offer?

• Develops therapeutic antibody discovery technologies.
• Utilizes proprietary transgenic animals for antibody generation.
• Offers access to diverse antibody repertoires and screening technologies.
• Focuses on next-generation therapeutics for various diseases.
• Provides bispecific antibody applications through innovative platforms.
• Collaborates with industry partners to enhance therapeutic development.

How Does OABI Make Money?

• Generates revenue through partnerships with pharmaceutical companies.
• Licenses its proprietary antibody discovery technologies.
• Offers customized solutions for therapeutic antibody development.
• Engages in research collaborations to advance product offerings.

What Industry Does OABI Operate In?

The biotechnology industry is experiencing significant growth, driven by advancements in genetic engineering and the increasing demand for innovative therapeutic solutions. The global biotechnology market is projected to reach approximately $2.4 trillion by 2028, with a compound annual growth rate (CAGR) of around 7.4%. Within this landscape, OmniAb, Inc. stands out due to its specialized focus on therapeutic antibody discovery, a critical area of development for next-generation therapeutics. The competitive landscape includes established players and emerging biotech firms, with a growing emphasis on personalized medicine and targeted therapies, positioning OmniAb as a key innovator in this dynamic market.

Who Are OABI's Key Customers?

• Pharmaceutical companies seeking innovative therapeutic solutions.
• Biotechnology firms requiring advanced antibody discovery technologies.
• Research institutions focused on therapeutic development.

OmniAb, Inc. (OABI) Valuation Context

Valued at $573M, OABI is classified as a small-cap stock. Relative to its peer group, OABI's quantitative score of 28/100 is below the peer average of 84/100.

OABI Revenue & Earnings Trend

In Q2 FY2026, OABI generated $13.4M in top-line revenue, marking a sequential decrease of 6.8%. The company recorded a net loss of $5.9M, with diluted EPS of $-0.05. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, OABI averaged $-0.09 in diluted EPS.

Company Profile

OmniAb, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in EmeryVille, US. The company is led by CEO Matthew W. Foehr. OABI has traded publicly since 2021.

Return on equity for OmniAb, Inc. stands at -16.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -7.7%, the inverse of the P/E and a quick read on earnings relative to price.

OmniAb, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 10.44 places it in the safe zone, indicating low near-term bankruptcy risk.

OmniAb, Inc. has missed Wall Street's EPS estimate in 4 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 5.5% above estimates on average.

Over the past six months, OmniAb, Inc. insiders filed 29 SEC Form 4 transactions — 8 sales and 21 purchases. On net that is roughly 1.2M shares acquired (about $2.1M) — insiders putting money in tends to read as conviction.

OABI Financials

OABI Latest News

OABI Analyst Consensus

OABI MoonshotScore

What Investors Ask About OmniAb, Inc. (OABI) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources